A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
Summary
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles\* of MDI-1228\_mesylate Ophthalmic Solution in healthy adult participants. Participants will receive either of the following treatment: * MDI-1228\_mesylate Ophthalmic Solution, or * Placebo\*\* Researchers will observe any changes in health (if any) in participants receiving the study treatment to evaluate the safety and tolerability\*\*\* of the study drug. Researchers will also collect several blood samples from participants to study PK profiles of the drug. Note: \*PK profiles: how the drug interacts with the body. \*\*placebo: a harmless substance that contains no active agents. \*\*\*tolerability: how well you can tolerate the drug.
Timeline
- Start
- 2023-10-06
- Primary completion
- 2024-04-30
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MDI-1228 | Unknown | 0.4 mg | Other |
| Subject | MDI-1228 | Unknown | 1.2 mg | Other |